BOLT BIOTHERAPEUTICS INC. - COMMON STOCK

Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers

17 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023

16 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers

28 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

12 Sep 2023 07:05:25 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Participate in September Investor Conferences

05 Sep 2023 15:15:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

07 Aug 2023 15:10:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer

03 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023

31 Jul 2023 16:27:56 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

25 May 2023 16:05:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

11 May 2023 15:05:01 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting

26 Apr 2023 09:00:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

29 Mar 2023 15:15:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies

29 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting

14 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference

28 Feb 2023 07:00:05 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present at February Investor Conferences

01 Feb 2023 07:00:02 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

14 Dec 2022 15:43:15 By Nasdaq GlobeNewswire

Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

10 Nov 2022 15:05:02 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meeting

07 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference

01 Nov 2022 07:00:02 By Nasdaq GlobeNewswire